Loading…
Aurinia Pharmaceuticals Inc. is projected to rise to $22.07 by 2027, a +40% move from its current price of $15.78. AUPH is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $15.38 | $15.78 | $16.20 | +0.02% |
| Jul 14 | $15.21 | $15.79 | $16.38 | +0.05% |
| Jul 15 | $15.09 | $15.79 | $16.52 | +0.07% |
| Jul 16 | $14.99 | $15.80 | $16.65 | +0.10% |
| Jul 17 | $14.90 | $15.80 | $16.75 | +0.12% |
| Jul 18 | $14.82 | $15.80 | $16.85 | +0.15% |
| Jul 19 | $14.75 | $15.81 | $16.94 | +0.17% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $14.75 | $15.81 | $16.94 | +0.17% |
| Week 2 | $14.36 | $15.83 | $17.46 | +0.34% |
| Week 3 | $14.07 | $15.86 | $17.88 | +0.51% |
| Week 4 | $13.83 | $15.89 | $18.25 | +0.69% |
| Week 5 | $13.63 | $15.92 | $18.58 | +0.86% |
| Week 6 | $13.45 | $15.94 | $18.89 | +1.03% |
| Week 7 | $13.29 | $15.97 | $19.18 | +1.20% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan.
Its approved therapy is LUPKYNIS (voclosporin), an oral treatment for adult patients with active lupus nephritis.
The company also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for potential autoimmune disease indications. Aurinia was founded in 1993 and is headquartered in Edmonton, Canada.
Aurinia Pharmaceuticals Inc. (AUPH) is trading at $15.80 today with a market cap of $2.03B. It is ranked 2038.
The stock's near-term technical picture shows bullish sentiment, with RSI(14) at 40, SMA50 at $15.99, and SMA200 at $14.78.
Support sits at $15.19 and resistance at $18.62, with a 30-day range from $13.27 to $18.81.
The forecast shows rising averages over time: 2026 average price is $15.80, progressing toward 2030 average of $39.11 and 2050 average of $262.44, with ROIs of 0% in 2026, 147.5% in 2030, and 1561% in 2050. The sentiment shifts from Neutral in 2026 to Bullish in later years.
A major floor 16.0% below — a decisive break under it would weaken the trend.
Price is testing support right now (3.0% away) — a key level to hold.
The nearest ceiling, 18.0% above — a clean break opens room to run.
A major ceiling 26.0% above — clearing it would confirm fresh momentum.
Key AUPH support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of AUPH market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $16.06 | Sell | $16.12 | Sell |
| MA 10 | $16.27 | Sell | $16.27 | Sell |
| MA 20 | $16.54 | Sell | $16.32 | Sell |
| MA 50 | $15.98 | Sell | $16.06 | Sell |
| MA 100 | $15.48 | Buy | $15.61 | Buy |
| MA 200 | $14.87 | Buy | $14.54 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 45.38 | Neutral |
| Stoch RSI (14) | 9.58 | Buy |
| CCI (20) | -73.89 | Neutral |
| Williams %R (14) | -90.73 | Info |
| MACD (12,26,9) | -0.13 | Sell |
| ROC (12) | -11.74 | Sell |
| Bollinger %B (20,2) | 0.27 | Neutral |
| Stochastic %K (14) | 9.27 | Buy |
| TRIX (15) | 0.16 | Buy |
| Awesome (5,34) | -0.07 | Sell |
| Ultimate (7,14,28) | 38.99 | Neutral |
| Momentum (10) | -1.77 | Sell |
| Aroon Osc (25) | -28.00 | Sell |
| Hull MA (9) | 16.23 | Sell |
| ADX (14) | 13.24 | Neutral |
| ATR (14) | 0.41 | Info |
The 30-day technical picture points to a bullish tilt while momentum remains cautious. The RSI sits at 40, suggesting room for movement without being overbought.
Prices are trading above the 200-day moving average at $14.78 and near the 50-day moving average at $15.99, indicating a constructive setup. Support is seen at $15.19 and resistance at $18.62, with the 30-day range spanning $13.27 to $18.81.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $13.95 | $15.78 | $21.54 | 0% | Neutral | |
| $17.64 | $22.07 | $29.18 | +40% | Bullish | |
| $21.76 | $27.96 | $38.31 | +77% | Bullish | |
| $25.68 | $33.74 | $47.54 | +114% | Bullish | |
| $29.42 | $39.41 | $56.84 | +150% | Bullish | |
| $31.05 | $42.34 | $62.34 | +168% | Bullish | |
| $34.06 | $47.22 | $70.82 | +199% | Bullish | |
| $36.47 | $51.34 | $78.30 | +225% | Bullish | |
| $41.90 | $59.87 | $92.71 | +279% | Bullish | |
| $54.22 | $78.56 | $123.41 | +398% | Bullish | |
| $69.15 | $106.75 | $178.06 | +577% | Bullish | |
| $156.00 | $268.49 | $488.79 | +16.0x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $13.95 | $15.78 | $18.76 | +0.00% |
| August 2026 | $13.70 | $16.15 | $19.54 | +2.35% |
| September 2026 | $13.59 | $16.14 | $19.73 | -0.09% |
| October 2026 | $13.29 | $15.87 | $19.58 | -1.65% |
| November 2026 | $13.67 | $16.40 | $20.39 | +3.33% |
| December 2026 | $14.28 | $17.21 | $21.54 | +4.94% |
Click any year to see its month-by-month AUPH forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, AUPH is projected to trade between $13.95 and $21.54, averaging $15.78 — a potential gain of 0% from today's $15.78. A consolidation phase looks the most probable path here.
Aurinia Pharmaceuticals Inc.'s 2027 outlook centres on $22.07, within a $17.64 to $29.18 range. That is up +40% on the projected 2026 average. That marks a +40% change versus current levels. Momentum favours further upside here.
By 2028, AUPH could reach as high as $38.31, with a base case around $27.96 and support toward $21.76 — roughly +77% from $15.78. Buyers look set to stay in control over this stretch.
Expect AUPH to range from $25.68 to $47.54 through 2029. The $33.74 average target implies a +114% move from current prices. That is up +21% on the projected 2028 average. Momentum favours further upside here.
The AUPH price prediction for 2030 points to an average of $39.41 (low $29.42, high $56.84) — a potential gain of +150% on today's $15.78. Buyers look set to stay in control over this stretch.
In 2031, AUPH is projected to trade between $31.05 and $62.34, averaging $42.34 — a potential gain of +168% from today's $15.78. That is up +7% on the projected 2030 average. Momentum favours further upside here.
Aurinia Pharmaceuticals Inc.'s 2032 outlook centres on $47.22, within a $34.06 to $70.82 range. That is up +12% on the projected 2031 average. That marks a +199% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, AUPH could reach as high as $78.30, with a base case around $51.34 and support toward $36.47 — roughly +225% from $15.78. Momentum favours further upside here.
Expect AUPH to range from $41.90 to $92.71 through 2034. The $59.87 average target implies a +279% move from current prices. That is up +17% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The AUPH price prediction for 2035 points to an average of $78.56 (low $54.22, high $123.41) — a potential gain of +398% on today's $15.78. Momentum favours further upside here.
In 2040, AUPH is projected to trade between $69.15 and $178.06, averaging $106.75 — a potential gain of +577% from today's $15.78. That is up +36% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Aurinia Pharmaceuticals Inc.'s 2050 outlook centres on $268.49, within a $156.00 to $488.79 range. That is up +152% on the projected 2040 average. That marks a +16.0x change versus current levels. Momentum favours further upside here.
Investing $1,000 in AUPH today (≈ 63.371356 AUPH) could be worth
$17,014.65
+$16,014.65 (+1601%) by 2050 · US Dollar
Based on the average projected AUPH price of $268.49 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in AUPHwould be worth at today's price.
$1,000 invested in AUPH on Jul 10, 2025 (≈ 111.982079 AUPH) would be worth
$1,767.08
+$767.08 (+76.7%) today · 1.77× · US Dollar
Based on a AUPH entry price of $8.93 vs. today's $15.78.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $15.61 | $1,010.89 | +1.1% |
| 1 month ago | $15.66 | $1,007.66 | +0.8% |
| 3 months ago | $15.76 | $1,001.27 | +0.1% |
| 6 months ago | $15.28 | $1,032.72 | +3.3% |
| 1 year ago | $8.93 | $1,767.08 | +76.7% |
| All time (5.0y) ago | $11.91 | $1,324.94 | +32.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our AUPH forecast.
Our base-case forecast reaches $32.00 around 2029.
Implied market cap at $32.00: $4.12B
The multi-year forecast paints a bullish path for Aurinia, with growing confidence in higher prices over time. By 2030, the average price is projected to be $39.11, with a min of $29.13 and a max of $56.56, and a forecasted ROI of 147.5%.
In 2040, the average price is expected to be $105.46, with a min of $68.06 and a max of $176.46, and a forecasted ROI of 567.4%, continuing the bullish stance from the prior years.
By 2050, the average price is projected at $262.44, with a min of $151.71 and a max of $479.54, and a forecasted ROI of 1561%, sustaining a bullish outlook across the long horizon.
Tap a question to reveal the answer.
2030 min $29.13, avg $39.11, max $56.56; ROI 147.5%; sentiment BULLISH.
From 2027 onward, the forecast is bullish with rising averages and positive ROI: 2027 avg $21.94, ROI 38.9%; 2028 avg $28.26, ROI 78.9%; 2029 avg $33.58, ROI 112.6%; 2030 avg $39.11, ROI 147.5%.
Yes. The forecast shows higher-price milestones including 2035 max $121.80, 2040 max $176.46, and 2050 max $479.54.
Current price is $15.80. The 30-day range is $13.27 to $18.81.
RSI(14) is 40; SMA50 is $15.99; SMA200 is $14.78; support is $15.19; resistance is $18.62. The 30-day range is $13.27–$18.81 and annualized volatility is 50%.
Aurinia Pharmaceuticals Inc. Community Discussion
0Share your Aurinia Pharmaceuticals Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.